Shearman & Sterling advised the underwriters of Tarsus Pharmaceuticals, Inc.’s follow-on public offering of 5,600,000 shares of common stock at a public offering price of $13.50 per share, resulting in gross proceeds to the company of approximately $75.6 million, before deducting underwriting discounts and commissions and offering expenses.
BofA Securities, Jefferies, Barclays and Raymond James acted as joint book-running managers for the offering and LifeSci Capital acted as lead manager.
Tarsus Pharmaceuticals, Inc. is a late clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates to address large market opportunities, initially in ophthalmic conditions, where there are limited treatment alternatives. It is advancing its pipeline to address several diseases across therapeutic categories including eye care, dermatology, and other diseases with high, unmet needs.
The Shearman & Sterling team below included associate Jordan Briggs (New York–Financial Institutions Advisory & Financial Regulatory).